trending Market Intelligence /marketintelligence/en/news-insights/trending/hot9tcapaahcsfjbzuclaa2 content esgSubNav
In This List

Cigna, Express Scripts execs talk deal impact; FDA chief warns pharma, payers

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cigna, Express Scripts execs talk deal impact; FDA chief warns pharma, payers

Here are the editors' top picks for the week ended March 9.

Cigna, Express Scripts $67B deal does not close door on other insurers: Execs

With Cigna Corp.'s $67 billion purchase of Express Scripts Holding Co., the last large, stand-alone pharmacy benefit manager and its roughly 100 million customers will be absorbed by a major health insurer.

FDA chief tells pharma, payers: Stop the shell games with biosimilar competitors

Brand-name-drug makers are plotting with payers to blunt the market incentives for companies to develop lower-cost versions of biologics, known as biosimilars, the head of the Food and Drug Administration asserted.

Officials urge pharma to drop egg-based flu vaccine, invest in new technologies

With a flu vaccine that was only 36% effective overall this season, the biopharmaceutical industry must move away from the egg-based process and "graduate to the 21st century," the U.S. government's top infectious disease expert told lawmakers.

Lundbeck on the challenge of schizophrenia research

H. Lundbeck A/S Chief Medical Officer Doug Williamson spoke to S&P Global Market Intelligence about advances the Danish company is making in finding new treatments for schizophrenia and about a recent collaboration with Vanderbilt University.

Ore. lawmakers approve disclosure requirements for drug price increases

Oregon lawmakers have sent to Gov. Kate Brown a bill that would require drug companies to disclose certain information when they raise prescription drug prices.

Teva stonewalling Senate opioid probe, top Democrat on Homeland panel charges

The Israeli company has been hampering a Senate investigation into the role drugmakers have played in driving the U.S. opioid epidemic, the top Democrat on the Homeland Security and Government Affairs Committee charged.

Battle brews over capping drug prices in Maryland

Pharmaceutical companies are fighting a bill in the state that could create the first-ever law allowing government to put price caps on drugs.

UnitedHealthcare to pass drugmaker rebates to consumers at pharmacy

UnitedHealth Group Inc. said it will pass along rebates it receives from drugmakers directly to about 7 million of its fully insured plan holders when they pick up their prescriptions at the pharmacy counter.

US health chief demands price transparency — or government will force change

It is time for healthcare providers, insurers, pharmacies and drugmakers to be more transparent about their pricing, and if they do not, the U.S. government has "plenty of levers to pull that would help drive this change," the U.S. health chief said.

Arkansas 3rd state to gain Medicaid work approval but held up on expansion cut

Arkansas became the third state in the U.S. to gain a waiver permitting it to require Medicaid beneficiaries who meet certain criteria to work in exchange for receiving health benefits, following Kentucky and Indiana.

Owlstone gains Li Ka-shing as investor in breathalyzer-like cancer diagnostic

The Cambridge, U.K.-based diagnostics company has attracted investment from Hong Kong tycoon Li Ka-shing to help bring its Breath Biopsy Breathalyzer-type testing for detecting lung cancer to market.